Clinical Trial Update: A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating the safety and initial efficacy of C-CAR011, a CD19-targeted CAR-T therapy, in adults with relapsed or refractory CD19-positiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd19-positive B-cell Acute Lymphoblastic Leukemia
• Or Refractory Acute Lymphoblastic Leukemia

Drugs mentioned

• C-CAR011

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | Status: UNKNOWN